Table 1.
Demographic and cancer characteristics and treatment for the study population
| Sex, n (%) | Histology, n (%) | 12 | |
| Female | 186 (41.5) | Adenocarcinoma | 433 (96.6) |
| Male | 262 (58.5) | Epidermoid carcinoma | 3 (0.7) |
| Neuroendocrine tumor | 11 (2.5) | ||
| Age, years n (%) | Melanoma | 1 (0.2) | |
| < 50 | 43 (9.6) | ||
| 50–69 | 209 (46.7) | Cancer location, n (%) | |
| 70–79 | 122 (27.2) | Colon | 290 (64.7) |
| ≥ 80 | 74 (16.5) | Rectum | 155 (34.6) |
| Anus | 3 (0.7) | ||
| Comorbidities, n (%) | |||
| Hypertension | 188 (41.9) | Synchronous metastasis, n (%) | 49 (10.9) |
| Diabetes mellitus | 130 (29) | ||
| Chronic obstructive pulmonary disease | 35 (7.8) | Preoperative chemoradiation, n (%)* | 80 (51.6%) |
| Asthma | 9 (2) | ||
| Coronary heart disease | 39 (8.7) | Surgical approach, n (%) | |
| Chronic kidney disease | 23 (5.1) | Laparoscopy | 317 (70.7) |
| Converted laparoscopy | 107 (23.9) | ||
| Immunosuppressive treatment, n (%) | 9 (2) | Laparotomy | 24 (5.4) |
| Corticosteroid treatment, n (%) | 8 (1.8) | Cancer stage, n (%) | |
| Stage 0 | 30 (6.7) | ||
| ASA grade, n (%) | Stage I | 99 (22) | |
| 1–2 | 328 (73.2) | Stage IIA | 109 (24.3) |
| 3–4 | 120 (26.8) | Stage IIB-IIC | 17 (3.8) |
| Stage IIIA | 20 (4.5) | ||
| Blood type, n (%) | Stage IIIB | 92 (20.6) | |
| A | 160 (41.2) | Stage IIIC | 30 (6.7) |
| B | 30 (7.7) | Stage IVA | 43 (9.6) |
| AB | 7 (1.8) | Stage IVB | 3 (0.7) |
| O | 191 (49.3) | Stage IVC | 5 (1.1) |
| Missing | 60 | ||
| Adjuvant chemotherapy, n (%) | 165 (36.8) | ||
| Under weight, n (%) | 9 (2) | ||
| Normal weight, n (%) | 205 (45.8) | ||
| Overweight, n (%) | 160 (35.7) | ||
| Obese, n (%) | 71 (15.8) | ||
| Morbid obese, n (%) | 3 (0.7) |
*Preoperative chemoradiation was only considered for the rectal cancer group